Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Study of Radioimmunotherapy With 90Y-Humanized MN-14 IgG Administered as a Single Dose to Patients With Refractory Metastatic/Recurrent Colorectal Carcinomas

NCT00040599 is registered in ClinicalTrials.gov with Gilead Sciences as lead sponsor.

NCT NCT00040599
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00040599 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Study of Radioimmunotherapy With 90Y-Humanized MN-14 IgG Administered as a Single Dose to Patients With Refractory Metastatic/Recurrent Colorectal Carcinomas
Lead sponsor
Gilead Sciences
Phase
Phase 1/2
Overall status
Completed
Start date
January 31, 2000
Completion date
January 31, 2004
Enrollment
72
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

colon cancer, colorectal cancer, colorectal carcinoma, colorectal neoplasms, colorectal tumor, rectal cancer